Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Part of paid clinical trials in Culver City, California.

Sponsor
Gedeon Richter Plc.
Study ID
NCT03817502
Phase
PHASE3
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
13 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Cariprazine — DRUG
    Cariprazine capsules, oral administration, once daily.
  • Placebo — DRUG
    Matching placebo capsules, oral administration, once daily.

Study Details

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Key Dates

Start date
Jun 6, 2019
Status verified
Oct 2025
Primary completion
Dec 15, 2026
Completion
Dec 15, 2026

Study Design

Enrollment
330 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cariprazine 1.5 mg/d
    Cariprazine capsules, oral administration, once daily.
  • Experimental: Cariprazine 4.5 mg/d
    Cariprazine capsules, oral administration, once daily.
  • Placebo Comparator: Placebo
    Matching placebo capsules, oral administration, once daily.

Primary Outcome Measure

Change from baseline in PANSS total score at Week 6 [ Time Frame: Baseline to Week 6 ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
ProScience Research GroupCulver CityCalifornia90230-
Atlanta Behavioral Research, LLCAtlantaGeorgia30338-
Atlanta Center for Medical ResearchAtlantaGeorgia30331-
Bloomfield Hills MIBloomfield HillsMichigan48302-
Precise Research CentersFlowoodMississippi39232-
UB Department of PsychiatryBuffaloNew York142515-
Manhattan Behavioral Medicine PLLCNew YorkNew York10036-
University of CincinnatiCincinnatiOhio45219-
Family Psychiatry of The WoodlandsThe WoodlandsTexas77381-

Find similar trials in Culver City, CA

By condition

Related Studies